717899-97-3
717899-97-3
Chemical Structure
CE-245677
- CAS No.: 717899-97-3
- Formula:C24H22Cl2N6O3
- Molecular Weight:513.38
IUPAC Name: 1-(5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxyphenyl)-3-(2,4-dichlorophenyl)urea
InChIKey: VFCRSIORGUNNGT-UHFFFAOYSA-N
SMILES: O=C(NC1=CC=C(Cl)C=C1Cl)NC2=CC(C(C3=CN(C(C)C)C4=NC=NC(N)=C43)=O)=CC=C2OC
Biological Activity: CE-245677 is a selective, reversible TrkA/B and Tie2 inhibitor. CE-245677 is effective in multiple pain models and inhibits tumor growth and the proliferation of Plasmodium falciparum during the erythrocytic stage[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CE-245677 | 98.00% | CE-245677 is a selective, reversible TrkA/B and Tie2 inhibitor. CE-245677 is effective in multiple pain models and inhibits tumor growth and the proliferation of Plasmodium falciparum during the erythrocytic stage. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.50
HY-122616PF-06273340 -
Similarity Score 0.50
HY-12327Trk-IN-1 -
Similarity Score 0.48
HY-12838RO5454948 -
Similarity Score 0.48
HY-16265AJI-101 hydrochloride -
Similarity Score 0.47
HY-16265JI-101 -
Similarity Score 0.47
HY-13686PQ401 -
Similarity Score 0.46
HY-161145EGFR/microtubule-IN-1 -
Similarity Score 0.46
HY-10981Lenvatinib -
Similarity Score 0.46
HY-123211WAY-150138 -
Explore the MedChemAI to find more analogs
References
- [1]. Bagal SK, et al. Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain. Journal of medicinal chemistry. 2018 Aug 09;61(15):6779-6800. [Content Brief]
- [2]. Yamada T, et al. Discovery and hit to lead optimization of macrocyclic peptides as novel tropomyosin receptor kinase A antagonists. Journal of Medicinal Chemistry. 2024 Jul 1;67(13):11197-208. [Content Brief]
- [3]. Bagal SK, et al. Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors. Journal of medicinal chemistry. 2019 Jan 10;62(1):247-265.
- [4]. Wang T, et al. Trk kinase inhibitors as new treatments for cancer and pain. Expert opinion on therapeutic patents. 2009 Mar 1;19(3):305-19.
- [5]. LaGreca S, et al. Identification of selective, orally active Tie2 kinase inhibitors and discovery of CE-245,677 and PF-371,989. Cancer Research. 2007 May 1;67(9_Supplement):3259-.
- [6]. Lotharius J, et al. Repositioning: the fast track to new anti-malarial medicines?. Malaria journal. 2014 Apr 14;13:143.
- [7]. Skerratt SE, et al. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. Journal of medicinal chemistry. 2016 Nov 23;59(22):10084-10099. [Content Brief]
